Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2050-2054

  Love, C D B ^a   Muir, B B ^a   Scrimgeour, J B ^a   Leonard, R C F ^a   Dillon, P ^a   Dixon, J M ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SCREENING; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HYSTEROSCOPY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY;

EID: 0032984748     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2050     Document Type: Article

References (30)

1. Fisher B, Costantino JP, Wickerham L, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project p-1 study. J Natl Cancer Inst 90:1371-1388, 1998
2. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237-238, 1985
3. Malfento JH: Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 84:82-84, 1990
4. Gusberg SB: Tamoxifen for breast cancer: Associated endometrial cancer. Cancer 65:1463-1464, 1990
5. Adami HO, Krusemo V, Bergkvist L, et al: On the age-dependent association between cancer of the breast and of the endometrium: A nationwide cohort study. Br J Cancer 55:77-80, 1987
6. Fisher B, Constantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994
7. Fornander T, Cedermask B, Mattson A, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 21:117-119, 1989
8. Mathew A, Chabon AB, Kabakow B, et al: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. N Y State J Med 90:207-208, 1990
9. van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452, 1994
10. Assikis VJ, Neven P, Jordan VC, et al: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32a: 1464-1476, 1996
11. Fleischer AC, Kalemeris GC, Entman SS: Sonographic depiction of the endometrium during normal cycles. Ultrasound Med Biol 12:271-277, 1986
12. Rutqvist LE, Cedermark B, Glas U, et al: The Stockholm trial on adjuvant tamoxifen in early breast cancer. Breast Cancer Res Treat 10:255-266, 1987
13. Sismondi P, Biglia N, Volpi E, et al: Tamoxifen and endometrial cancer. Ann N Y Acad Sci 734:310-321, 1994
14. Jaiyesimi IA, Buzdar AU, Decker DA, et al: Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13:513-529, 1995
15. Friedl A, Jordan VC: What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 31:27-39, 1994
16. Cohen CJ, Rahaman J: Endometrial cancer: Management of high risk and recurrence including the tamoxifen controversy. Cancer 76:2044-2052, 1995
17. Cohen I, Altaras MM, Shapira J, et al: Postmenopausal tamoxifen treatment and endometrial pathology. Obstet Gynecol Surv 49:823-829, 1994
18. Bourne TH, Evaluating the endometrium of postmenopausal women with transvaginal ultrasonography. Ultrasound Obstet Gynecol 6:75-80, 1995
19. Cecchini S, Ciatto S, Bonardi R, et al: Screening by ultra-sonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 60:409-411, 1996
20. Nasri M, Shephard J, Setchell M, et al: The role of vaginal scanning in the measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 98:470-475, 1991
21. Touraine P, Driguez P, Castier I, et al: Lack of induction of endometrial hyperplasia with tamoxifen. Lancet 345:254-255, 1995
22. Ismail SI: Gynaecological effects of tamoxifen. J Clin Pathol 52:83-88, 1999
23. Cohen I, Altaras MM, Shapira J, et al: Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol 15:152-157, 1996
24. Anteby E, Yagel S, Zacut D, et al: False sonographic appearance of endometrial neoplasia in postmenopausal women treated with tamoxifen. Lancet 340:433-444, 1992
25. Goldstein SR, Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 170:447-451, 1994
26. Hulka CA, Hall DA: Endometrial abnormalities associated with tamoxifen therapy for breast cancer: Sonographic and pathologic correlation. AJR Am J Roentgenol 160:809-812, 1993
27. Ciatto S, Cecchini S, Bonardi R, et al: Ultrasonography surveillance of endometrium in breast cancer patients on adjuvant tamoxifen. Lancet 344:60, 1994 (letter)
28. Neven P, De Muylder X, Can Velle Y, et al: Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 351:36, 1998 (letter) .
29. Langer RD, Pierce JJ, O'Hanlon KA, et al: Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 337:1792-1798, 1997
30. Bertelli G, Venturini M, Del Mastro L, et al: Tamoxifen and the endometrium: Findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 47:41-46, 1998